Zhaowu Zeng

Dr. Zhaowu Zeng

Hangzhou Normal University
orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2011 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
ZZZhaowu Zeng
Zhaowu Zeng
JWJun Jie Wang
Jun Jie Wang
RXRen Zhong Xiao
Ren Zhong Xiao
TXTian Xie
Tian Xie
GZGuang Lin Zhou
Guang Lin Zhou
SWShu Ling Wang
Shu Ling Wang
Chitosan nanoparticles are good drug carriers because of their good biocompatibility and biodegradability, and can be readily modified. As a new drug delivery system, they have attracted increasing attention for their wide applications in, for example, loading protein drugs, gene drugs, and anticancer chemical drugs, and via various routes of administration including oral, nasal, intravenous, and ocular. This paper reviews published research on chitosan nanoparticles, including its preparation methods, characteristics, modification, in vivo metabolic processes, and applications.

1 April 2020 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
JLJie Li
Jie Li
JZJiaqian Zhao
Jiaqian Zhao
Tiantian TanTiantian Tan
Tiantian Tan
MLMengmeng Liu
Mengmeng Liu
ZZZhaowu Zeng
Zhaowu Zeng
TXTian Xie
Tian Xie
Abstract: Gliomas are the most common tumor of the central nervous system. However, the presence of the brain barrier blocks the effective delivery of drugs and leads to the treatment failure of various drugs. The development of a nanoparticle drug delivery system (NDDS) can solve this problem. In this review, we summarized the brain barrier (including blood–brain barrier (BBB), blood–brain tumor barriers (BBTB), brain–cerebrospinal fluid barrier (BCB), and nose-to-brain barrier), NDDS of glioma (such as passive targeting systems, active targeting systems, and environmental responsive targeting systems), and NDDS efficacy improvement strategies and deficiencies. The research prospect of drug-targeted delivery systems for glioma is also discussed.

1 October 2018 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
BZBingtao Zhai
Bingtao Zhai
YZYiying Zeng
Yiying Zeng
ZZZhaowu Zeng
Zhaowu Zeng
NZNana Zhang
Nana Zhang
CLChenxi Li
Chenxi Li
TXTian Xie
Tian Xie
β-elemene is a noncytotoxic Class II antitumor drug extracted from the traditional Chinese medicine Curcuma wenyujin Y. H. Chen et C. Ling. β-elemene exerts its effects by inhibiting cell proliferation, arresting the cell cycle, inducing cell apoptosis, exerting antiangiogenesis and antimetastasis effects, reversing multiple-drug resistance (MDR), and enhancing the immune system. Elemene injection and oral emulsion have been used to treat various tumors, including cancer of the lung, liver, brain, breast, ovary, gastric, prostate, and other tissues, for >20 years. The safety of both elemene injection and oral emulsion in the clinic has been discussed. Recently, the secondary development of β-elemene has attracted the attention of researchers and made great progress. On the one hand, studies have been carried out on liposome-based systems (including solid lipid nanoparticles [SLNs], nanostructured lipid carriers [NLCs], long-circulating liposomes, active targeting liposomes, and multidrug-loaded liposomes) and emulsion systems (including microemulsions, self-emulsion drug delivery systems [SEDDSs], and active targeting microemulsion) to solve the issues of poor solubility in water, low bioavailability, and severe phlebitis, as well as to improve antitumor efficacy. The pharmacokinetics of different drug delivery systems of β-elemene are also summarized. On the other hand, a number of highly active anticancer β-elemene derivatives have been obtained through modification of the structure of β-elemene. This review focuses on the two drug delivery systems and derivatives of β-elemene for cancer therapy.

1 November 2010 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
ZZZhaowu Zeng
Zhaowu Zeng
RXRen Zhong Xiao
Ren Zhong Xiao
GZGuang Lin Zhou
Guang Lin Zhou
JWJun Jie Wang
Jun Jie Wang
FLFan Zhu Li
Fan Zhu Li
AWAn Ming Wang
An Ming Wang
Due to their small particle size and large and modifiable surface, nanoparticles have unique advantages compared with other drug carriers. As a research focus in recent years, polyethylene glycol–polylactic acid (PEG–PLA) block copolymer and its end-group derivative nanoparticles can enhance the drug loading of hydrophobic drugs, reduce the burst effect, avoid being engulfed by phagocytes, increase the circulation time of drugs in blood, and improve bioavailability. Additionally, due to their smaller particle size and modified surface, these nanoparticles can accumulate in inflammation or target locations to enhance drug efficacy and reduce toxicity. Recent advances in PEG–PLA block copolymer nanoparticles, including the synthesis of PEG–PLA and the preparation of PEG–PLA nanoparticles, were introduced in this study, in particular the drug release and modifiable characteristics of PEG–PLA nanoparticles and their application in pharmaceutical preparations.

26 September 2021 in Journal of Nanobiotechnology
Verified
Journal Article
Open access
PDF file
JLJie Li
Jie Li
HZHuamin Zeng
Huamin Zeng
YYYu You
Yu You
RWRongrong Wang
Rongrong Wang
TTTiantian Tan
Tiantian Tan
TXTian Xie
Tian Xie
Background: Effective treatment of glioma requires a nanocarrier that can cross the blood–brain barrier (BBB) to target the tumor lesion. In the current study, elemene (ELE) and cabazitaxel (CTX) liposomes were prepared by conjugating liposomes with transferrin (Tf) and embedding the cell membrane proteins of RG2 glioma cells into liposomes (active-targeting biomimetic liposomes, Tf-ELE/CTX@BLIP), which exhibited effective BBB infiltration to target glioma. Results: The findings showed that Tf-ELE/CTX@BLIP was highly stable. The liposomes exhibited highly significant homologous targeting and immune evasion in vitro and a 5.83-fold intake rate compared with classical liposome (ELE/CTX@LIP). Bioluminescence imaging showed increased drug accumulation in the brain and increased tumor penetration of Tf-ELE/CTX@BLIP in orthotopic glioma model nude mice. Findings from in vivo studies indicated that the antitumor effect of the Tf-ELE/CTX@BLIP led to increased survival time and decreased tumor volume in mice. The average tumor fluorescence intensity after intravenous administration of Tf-ELE/CTX@BLIP was 65.2, 12.5, 22.1, 6.6, 2.6, 1.5 times less compared with that of the control, CTX solution, ELE solution, ELE/CTX@LIP, ELE/CTX@BLIP, Tf-ELE/CTX@LIP groups, respectively. Histopathological analysis showed that Tf-ELE/CTX@BLIP were less toxic compared with administration of the CTX solution. Conclusion: These findings indicate that the active-targeting biomimetic liposome, Tf-ELE/CTX@BLIP, is a promising nanoplatform for delivery of drugs to gliomas. Graphic

1 August 2012 in International Journal of Nanomedicine
Verified
Journal Article
Open access
RXRenzhong Xiao
Renzhong Xiao
RWRongrong Wang
Rongrong Wang
ZZZhaowu Zeng
Zhaowu Zeng
LXLili Xu
Lili Xu
JWJunjie Wang
Junjie Wang
Peer reviewed article authored by (Wang R, Xiao R, Zeng Z, Xu L, Wang J). Read article or submit your manuscript for publishing.